Mainz Biomed Bv Stock Fundamentals
| MYNZ Stock | USD 6.79 0.53 7.24% |
Mainz Biomed BV fundamentals help investors to digest information that contributes to Mainz Biomed's financial success or failures. It also enables traders to predict the movement of Mainz Stock. The fundamental analysis module provides a way to measure Mainz Biomed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mainz Biomed stock.
At this time, Mainz Biomed's Depreciation And Amortization is fairly stable compared to the past year. Gross Profit is likely to rise to about 535.1 K in 2024, despite the fact that Net Interest Income is likely to grow to (769.1 K). Mainz | Select Account or Indicator |
Mainz Biomed BV Company Return On Asset Analysis
Mainz Biomed's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Mainz Biomed Return On Asset | -0.99 |
Most of Mainz Biomed's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mainz Biomed BV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Mainz Total Assets
Total Assets |
|
Based on the latest financial disclosure, Mainz Biomed BV has a Return On Asset of -0.9924. This is 88.66% lower than that of the Biotechnology sector and 86.82% lower than that of the Health Care industry. The return on asset for all United States stocks is notably higher than that of the company.
Mainz Biomed BV Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mainz Biomed's current stock value. Our valuation model uses many indicators to compare Mainz Biomed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mainz Biomed competition to find correlations between indicators driving Mainz Biomed's intrinsic value. More Info.Mainz Biomed BV is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Mainz Biomed's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mainz Biomed's earnings, one of the primary drivers of an investment's value.Mainz Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mainz Biomed's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mainz Biomed could also be used in its relative valuation, which is a method of valuing Mainz Biomed by comparing valuation metrics of similar companies.Mainz Biomed is currently under evaluation in return on asset category among its peers.
Mainz Biomed ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mainz Biomed's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mainz Biomed's managers, analysts, and investors.Environmental | Governance | Social |
Mainz Fundamentals
| Return On Equity | -43.34 | ||||
| Return On Asset | -0.99 | ||||
| Operating Margin | (18.83) % | ||||
| Current Valuation | 21.95 M | ||||
| Shares Outstanding | 2 M | ||||
| Shares Owned By Insiders | 5.79 % | ||||
| Shares Owned By Institutions | 0.25 % | ||||
| Number Of Shares Shorted | 3.57 M | ||||
| Price To Book | 1.72 X | ||||
| Price To Sales | 15.98 X | ||||
| Revenue | 895.48 K | ||||
| Gross Profit | 177.62 K | ||||
| EBITDA | (25.01 M) | ||||
| Net Income | (26.3 M) | ||||
| Cash And Equivalents | 26.01 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 7.42 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 10.83 X | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (21.94 M) | ||||
| Short Ratio | 0.76 X | ||||
| Earnings Per Share | (46.97) X | ||||
| Target Price | 2.0 | ||||
| Number Of Employees | 65 | ||||
| Beta | 0.076 | ||||
| Market Capitalization | 14.66 M | ||||
| Total Asset | 15.41 M | ||||
| Retained Earnings | (69.33 M) | ||||
| Working Capital | (257.15 K) | ||||
| Net Asset | 15.41 M |
About Mainz Biomed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mainz Biomed BV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mainz Biomed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mainz Biomed BV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 138.9 K | 94.1 K | |
| Total Revenue | 895.5 K | 611.1 K | |
| Cost Of Revenue | 385.8 K | 406.2 K | |
| Stock Based Compensation To Revenue | 4.47 | 4.25 | |
| Sales General And Administrative To Revenue | 14.98 | 10.46 | |
| Research And Ddevelopement To Revenue | 10.71 | 11.25 | |
| Capex To Revenue | 2.12 | 2.23 | |
| Revenue Per Share | 0.06 | 0.05 | |
| Ebit Per Revenue | (29.75) | (31.24) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| IBTA | Ibotta, | |
| DTST | Data Storage Corp | |
| ESRT | Empire State Realty |
Additional Tools for Mainz Stock Analysis
When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.